were mainly found in MP-CMML cases. Mutations of ASXL1 correlated with an evolution toward an acutely transformed state: all CMMLs that progressed to acute phase were mutated and none of the unmutated patients had evolved to acute leukaemia. The overall survival of ASXL1 mutated patients was lower than that of unmutated patients.
Keywords: chronic myelomonocytic leukaemia, gene mutation, ASXL1, prognosis. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Vardiman, 2002) . Despite recent molecular improvements in the classification of myeloid neoplasms, diagnosis of CMML is still based on cytological criteria including persistent peripheral monocytosis greater than 1 x 10 9 /L, less than 20% blasts in the blood or bone marrow (BM) and bone marrow dysplasia in one or more myeloid lineage. The only molecular criterium is the absence of BCR-ABL transcript (Bennett et al, 1982 , Vardiman, 2002 . Because the blast number is a prognostic factor, CMML is divided in two types: type 1 with fewer than 5% blasts in the blood and 10% blasts in the bone marrow, and type 2 with between 5 to 19% in the blood or 10 to19% in the bone marrow (Vardiman, 2002; Vardiman et al, 2009 ).
Classification of CMML has always been a matter of debate based on the two distinct clinical presentations: dysplastic with symptomatic complications of cytopenia, and proliferative with splenomegaly or hepatomegaly. In 1994, on the basis of an arbitrary threshold of peripheral leukocyte count (WBC), a dysplastic (<13 x 10 9 /L) and a proliferative (> 13 x 10 9 /L) forms have been recognised by the FAB group (Bennett, 1994) , which we will call here MD-CMML and MP-CMML, respectively. Until recently, neither biologic nor prognostic data allowed the support of this distinction except that MP-CMML seemed to have more RAS mutations (Padua et al, 1988; Padua et al, 1998) . Recently, new molecular alterations have been described in CMML. We and others have showed a high frequency of RUNX1 and TET2 mutations Kosmider et al, 2009b; Kuo et al, 2009 ). Mutations of TET2 and CBL occur in 50% (Kosmider et al, 2009b) (Makishima et al, 2009 ) of CMML cases, respectively. Recently, we described exon 12 mutations of ASXL1 with a frequency about 44% (Gelsi-Boyer et al, 2009 ).
Currently, the impact of these alterations remains to be determined and the biological and clinical presentations are still heterogeneous and benefit from opposite therapeutics: cytotoxic in the MP form, haematopoietic growth factors in the MD form.
We propose here a comprehensive study of molecular alterations in a series of 53 CMMLs using genome-wide, high-density array-comparative genomic hybridisation (aCGH) and exon-coding sequencing of 13 candidate genes. We show that ASXL1 mutations are associated with MP-CMML and that MP-CMMLs have overall more alterations. Most importantly, we show that mutations in ASXL1 correlate with acute transformation of CMML and that the overall survival rate is lower in ASXL1 mutated patients than in unmutated patients.
Patients and methods

Patients and samples
A series of consecutive bone marrow samples obtained from 53 patients, who all signed an informed consent, were collected. Among these were 31 MP-CMMLs and 22 MD-CMMLs as initially defined by the FAB group with a leukocyte count superior or inferior to 13 x 10 9 /L, respectively. The median age and leukocytosis were 74 years and 30 x 10 9 /L respectively in the MP-CMML group and 76.5 years and 9 x 10 9 /L respectively in the MD-CMML group. The main clinical and biological data of the 53 samples are presented in Supplementary Table I for an independent solid tumour. A normal karyotype was observed in 40 patients (20 MP-CMMLs and 20 MD-CMMLs); a del(20q)(q11q13) was found in 3 patients (2 MP-CMMLs and 1 MD-CMML); a trisomy of a commonly affected chromosome (8, 19, 21) was encountered in 4 MP-CMMLs. One MD-CMML had an 11q inversion, one MP-CMML had a t(10;11)(p12;p15) and one MP-CMML had a t(1;3)(p36;q21). Nucleic acid extraction was done as previously described .
Array comparative genomic hybridisation (aCGH)
aCGH was done on all samples but two (HD-0397, HD-0715). Some of the results have been published on 38 cases Gelsi-Boyer et al, 2009 ). Genomic imbalances were analysed by aCGH using 244K CGH Microarrays (Hu-244A, Agilent Technologies, Massy, France) as previously described Etienne et al, 2007) . Scanning was done with Agilent Autofocus Dynamic Scanner (G2565BA, Agilent Technologies). Data analysis was done as previously described (Murati et al, 2003; Barrett et al 2004,) and visualised with CGH Analytics 3.4 software (Agilent Technologies). Extraction data (log 2 ratio) was done with CGH analytics while normalised and filtered log 2 ratios were obtained from « Feature extraction » software (Agilent Technologies). Copy number changes were characterised as reported Etienne et al, 2007) . Polymerase chain reaction (PCR) and direct sequencing were done using standard conditions with gene-specific primers designed to amplify coding sequence of ASXL1 (exon 12), CBL (exons 8, 9), FLT3 (exons 14, 15, 20) , IDH1/2 (exon 4), JAK2 (exon 14), K, NRAS (exons 1, 2), NPM1 (exon 12), PTPN11 (exons 3, 11), RUNX1 (exons 1 to 8), TET2 (exons 3 to 11) and WT1 (exons 7, 9) as previously described Gelsi-Boyer et al, 2009 , Kosmider et al 2009a , Carbuccia et al, 2010 Kosmider, et al 2009b) . Primers are described in Gelsi-Boyer et al. (2008) and Rocquain et al. (2010b) . Most PCR amplifications were done in a total volume of 25 µl PCR mix containing at least 10 ng template DNA, Taq buffer, 200 µmol of each deoxynucleotide triphosphate, 20 pmol of each primer and 1 unit of Hot Star Taq (Qiagen). PCR amplification conditions were as follows: 95°C 10 min;
DNA sequencing
95°C 30 sec, variable temperature 30 sec, 72°C 45 sec for 30 cycles; 72°C 10 min.
PCR products were purified using Millipore plate MSNU030. Two microliters of the purified PCR products were used for sequencing using the Big Dye terminator v1.1 kit (Applied Biosystems). After G50 purification, sequences were loaded on an ABI 3130XL automat (Applied Biosystems). The sequence data files were analysed using the SeqScape software and all mutations were confirmed on an independent PCR product.
Statistical Analysis
Clinical and biological factors were taken at the time of sampling whose date corresponds to the search for molecular alterations. The different quantitative biological variables were compared by the Student test (t-test) and prevalence of mutations or alterations detected by karyotype or aCGH by the Chi-square test.
Overall survival was defined by the time from the date of diagnosis to the date of Proportional Hazard and Fine and Gray models were used in a multivariate approach. Cumulative incidences of AML transformations were estimated by the Prentice method. All statistical tests were two-sided at the 5% level of significance.
Results
aCGH profiles of CMML
We established the aCGH profiles of 51 of the 53 CMML cases. Results are summarized in Table I . aCGH revealed alterations that were observed by conventional cytogenetics (9/51) except for 3 patients with balanced translocations (HD-0201, HD-0316, HD-0178), and for case HD-0367 with a del(20)(q11q13) for which aCGH did not show a frank deletion at 20q probably due to the low number of affected cells. For nine cases (17%) aCGH detected rare and limited losses or gains, not visible on the karyotype. They affected very few genes, as previously described Adélaïde et al, 2010; Rocquain et al, 2010a) , including some with known tumour suppressor function and leukaemogenic activity (NF1, RB1 and TET2). In 70% of cases (36/51) no copy number aberrations were observed. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We studied coding sequences of 13 genes on the 53 cases (Table I) . Some results have been previously published Gelsi-Boyer et al, 2009; Kosmider et al, 2009b) . In 25 cases (49%) we found 20 frameshift (including 7 times the same p.Gly646Trpfsx12) and 5 nonsense mutations in ASXL1 exon 12. For three patients (HD-0228, HD-0328, HD-0370), we could demonstrate that the mutation was acquired because the mutation was absent from buccal smear DNA (not shown). CBL exon 8 mutations were found in about 10% of cases (5/47); one case (HD-0223) had a homozygous mutation. One case (HD-0367) had an internal tandem duplication of FLT3. We found 5 IDH mutations in 48 cases (10%); all were in IDH2 (4 times the same p.Arg140Gln). Seven patients out of the 53 cases (13%) had a K or NRAS mutation. We previously examined the sequence of exons 3 and 13 of the PTPN11 gene and mutations were found in two cases .
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Twelve out of 53 patients (21%) were mutated for RUNX1 and 36% of patients were mutated for TET2. No mutation was found in NPM1, JAK2 and WT1. On the basis of small deletions detected by aCGH and spanning only few genes, we searched for mutations in an additional set of candidate genes: ASXL2, BRAF, CBFB, CTNNB1, KDM3B, KDM6A/UTX, KDM6B, NFIA, PYGO1, SPI1, RAF1, and TET3 but failed to find any mutations (unpublished data) except in one patient (HD-0398) for which a mutation in NFIA exon 2 was found and previously reported (Bernard et al, 2008) .
MP-and MD-CMMLs show quantitative differences in molecular alterations
Genomic alterations detected by conventional cytogenetics or aCGH were different in MP-and MD-CMML (Table I) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We compared the prevalence of the mutated genes in MP and MD-CMML.
Nineteen of the 25 ASXL1 mutations were found in 30 MP-CMMLs vs 6 in 22 MD-CMMLs. Mutations in ASXL1 but not in RUNX1 or TET2 were more frequent in MP than in MD-CMMLs (p=0.03) ( p=0.008). Overall, the number of mutations (ASXL1 and proliferation genes) was higher in MP than in MD-CMMLs (p=0.018).
Altogether, molecular events (mutations and genomic alterations) were more frequent in MP-CMMLs (69/273 events) than in MD-CMMLs (26/172) (p=0.0018).
Correlations between ASXL1 mutation and clinical and biological features in CMML
The main clinical and biological features of 51 CMML cases were examined with respect to ASXL1 mutations ( Table II) . The presence of an ASXL1 mutation was associated with higher WBC (30 x 10 9 /L vs 15 x 10 9 /L) (p=0.006), higher blood (p=0.005) and bone marrow monocytosis (p=0.04) and with lower level of blood haemoglobin (p=0.03). No difference was noted in mean cell volume, blood count of neutrophils and platelets, or bone marrow blasts. In MP-CMMLs, ASXL1 mutation correlated with a lower level of haemoglobin (p=0.03) and platelet count (p=0.002) Among ASXL1 mutated cases (25/51), eleven (9 MP and 2 MD) had evolved to acute transformation (Table II) . For one case (HD-0398) DNA of the acute phase was available; we looked for the ASXL1 mutation and found the same alteration (not shown). In contrast, no acute transformation was observed in the unmutated cases.
In other words, all transformed cases had an ASXL1 mutation but not all ASXL1 mutated cases had progressed to AML. ASXL1 mutation and acute transformation were correlated (p=0.0005). Patient HD-0316 had progressed to acute phase but was not included in the 51 patients since we could not determine the ASXL1 status because of lack of material at either stage.
Overall survival (median follow-up of 29.5 months) was analysed for the 53 patients. Median overall survival was 27.6 months ( Fig 1A) . ASXL1 status could be determined at the time of diagnosis for 51 patients. Kaplan-Meier analysis showed a lower overall survival rate in the ASXL1 mutated patients (Fig 1B) . With respect to MP/MD form, only a trend to a better survival of the MD patients was observed (not shown). Within MP-CMML patients, cases mutated for ASXL1 had a poorer survival than the unmutated cases (not shown). We determined the cumulative incidence of AML ( Fig 1C) and observed that all the patients who developed AML did so within two years and that ASXL1 mutation had a strong impact on AML incidence (Fig 1D) .
We did the same analysis for TET2 mutational status. In contrast to ASXL1, TET2 had no impact on overall survival (not shown). Given the low number of events for the other genes we did not look for any other clinical or biological correlation.
Univariate analysis of time-to-AML was done on 50 patients using as variables ASXL1 and TET2 mutational status and MP/MD form, monocytosis, blast count in mutation is an unfavourable prognostic factor for overall survival and progression to AML.
Discussion
We established the genomic profiles of a series of 53 CMMLs by using aCGH and sequencing of 13 candidate genes.
ASXL1 is the most frequently mutated gene in CMML
In more than two-thirds of cases aCGH profiles did not show any copy number aberrations. In few cases, small copy number aberrations were indicative of genes known (NF1, RB1, TET2) or suspected (SH3KPB1, RAD21) (Adélaïde et al, 2010 ; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Rocquain et al, 2010a) to be involved in leukaemogenesis. MP-CMMLs had more genomic alterations than MD-CMMLs.
We studied 13 candidate genes. We classified these genes into three groups.
The first group comprised five known and potential tumour suppressors and transcription factors, the second group six genes associated with kinase activity, signalling pathways and proliferation, and the third group the two IDH genes.
Hypothetically, CMML could result from a combination of mutation(s) in each of these groups, and perhaps more yet-to-be discovered mutations. Overall, mutations of ASXL1, RUNX1 and TET2 were prominent in particular in MP-CMMLs but the difference between the two forms was not statistically significant for the three genes taken as a whole (p=0.19). Mutations in these three genes were not mutually exclusive. This is in contrast to what we observed in myelodysplastic syndromes (MDS) and acute myeloid leukaemia where RUNX1 and TET2 mutations were mutually exclusive but could each be associated with ASXL1 mutations (Rocquain et al., 2010b) . We have no explanation for this observation. ASXL1 mutations are found in all myeloid neoplasms Gelsi-Boyer et al, 2009; Carbuccia et al, 2010; Kosmider et al, 2009a; Boultwood et al, 2010a; Boultwood et al, 2010b; Sugimoto et al, 2010; Tefferi, 2010) . In the present study ASXL1 appeared as the most frequently mutated gene in CMML, as it is in MDSs (Boultwood et al, 2010a; Rocquain et al, 2010b) . In MDSs, ASXL1 mutations are found in high-risk cases.
As previously observed mutations in the second group of "proliferation" genes were mutually exclusive. The frequency of mutations of CBL was in the range of what was observed recently (Makishima et al, 2009 ). With two exceptions (a CBL mutation and an NF1 deletion detected by aCGH), mutations in these genes were a hallmark of MP-CMML and may explain the proliferative (Ricci et al, 2010) . However, in our series we did not find any JAK2 mutation. Overall, the number of mutations (ASXL1 and proliferation genes) was higher in MP-CMML than in MD-CMML. This is a molecular basis to the separation of CMML in MP and MD forms initially defined by the FAB group.
However, the equal number of mutations of RUNX1 and TET2 in both forms suggests a common mechanism of oncogenesis.
ASXL1 mutation is associated with poor prognosis and acute transformation of CMML
The MP and MD classification may have a molecular basis (Gelsi-Boyer et al, 2007 ; this work) but had no significant impact on prognosis in our series. Several studies have similarly found that this classification does not by itself offer enough prognostic information (Germing et al, 1998; Nosslinger et al, 2001; Gonzalez-Medina et al, 2002) . We have here shown that, in contrast, ASXL1 mutation is associated with both poor overall survival and acute transformation. In our series, no unmutated cases had evolved to acute phase whereas the cases that had progressed to acute leukaemia were all mutated (except for one case for which we could not determine the ASXL1 status 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 0230 and HD-0660, whose ASXL1 mutated CMML progressed from CMML1 to CMML2. For mutated patients still alive it could be a question of time. If this were the case ASXL1 mutation could be used to predict the risk of progression of CMML to acute leukaemia. In contrast, TET2 mutations had no impact. A previous study had found prognostic impact of TET2 mutation but only in CMML1 (Kosmider et al, 2009b) .
ASXL1 mutation is associated with aggressive forms in other myeloid disorders, including high-risk MDSs, primitive myelofibrosis ), secondary acute myeloid leukaemias (Carbuccia et al, 2010) . If confirmed on a larger series the data would endow ASXL1 with such a prognostic value that its mutational status may be systematically determined in hospital setting and that the management of patients with mutation may be adapted. It could also be interesting to classify CMMLs studied in clinical trials according to ASXL1 status.
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